Intracoronary β-Irradiation With a Rhenium-188–Filled Balloon Catheter

Höher, Martin; Wöhrle, Jochen; Wohlfrom, Markus; Kamenz, Joachim; Nusser, Thorsten; Grebe, Olaf; Hanke, Hartmut; Kochs, Matthias; Reske, Sven N.; Hombach, Vinzenz; Kotzerke, Jörg

doi:10.1161/01.cir.0000074203.66371.29

Cited by 39 publications

(9 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alternatively, NIS may be used to transport other radioisotopes such as the ␤-emitter 188 Rhenium, which could potentially be more effective than 131 I because of higher radiation (44,45). How- ever, the only clinical experience with this radioisotope is limited to its use for endovascular brachytherapy or treatment of osseous metastasis (46,47).…”

Section: Discussionmentioning

confidence: 99%

The Na+/I− Symporter Mediates Iodide Uptake in Breast Cancer Metastases and Can Be Selectively Down-Regulated in the Thyroid

Wapnir¹,

Goris

Yudd

et al. 2004

Clinical Cancer Research

108

View full text Add to dashboard Cite

Results: I -uptake was noted in 25% of NIS-expressing tumors (two of eight). The remaining cases did not show NIS expression or activity. Thyroid I -uptakes were decreased to <2.8% at 24 h in T 3 -treated patients and 1/100 normal with T 3 /MMI. Uptake (2.9%) was calculated in a peribronchial metastasis on 131 I dosimetry scans at 4 h with disappearance of the signal by 24 h. We estimated a therapeutic dose of 3000 cGy could be achieved in this metastasis with 100 mCi of 131 I if the tumor exhibited the same dynamics as the T 3 /MMI-suppressed thyroid.Conclusions: This is the first article of in vivo, scintigraphically detected, NIS-mediated I -accumulation in human BCM. T 3 /MMI down-regulation of thyroid NIS makes 131 I-radioablation of BCM possible with negligible thyroid uptake and radiation damage.

show abstract

Section: Discussionmentioning

confidence: 99%

The Na+/I− Symporter Mediates Iodide Uptake in Breast Cancer Metastases and Can Be Selectively Down-Regulated in the Thyroid

Wapnir¹,

Goris

Yudd

et al. 2004

Clinical Cancer Research

108

View full text Add to dashboard Cite

show abstract

“…The total segment included edge effects 5 mm proximal and distal to the stented segment according to trials with brachytherapy. 20 Furthermore, the occurrence of major adverse cardiac events, including death, MI, and need for reintervention (angioplasty or surgical revascularization), was analyzed. Group comparisons were done on a per-lesion basis.…”

Section: Discussionmentioning

confidence: 99%

“…Angiographic measurements were done offline with Pie Medical software version 2.1 (Pie Medical Imaging) as previously described. 20,21 …”

Section: Quantitative Coronary Angiographymentioning

confidence: 99%

Pioglitazone Reduces Neointima Volume After Coronary Stent Implantation

et al. 2005

Self Cite

View full text Add to dashboard Cite

Background-Restenosis requiring reintervention limits the long-term success after coronary stent implantation.Thiazolidinediones, like pioglitazone or rosiglitazone, are oral antidiabetic drugs with additional antirestenotic properties. In a randomized, placebo-controlled, double-blind trial, we examined the effect of 6-month pioglitazone therapy on neointima volume after coronary stenting in nondiabetic coronary artery disease patients. Methods and Results-Fifty nondiabetic patients after coronary stent implantation were randomly assigned to pioglitazone (30 mg daily; pio) or placebo (control) treatment in addition to standard therapy, and neointima volume was assessed by intravascular ultrasound at the 6-month follow-up. Both groups were comparable with regard to baseline characteristics, angiographic lesion morphology, target vessel, and length of the stented segment. In addition, there were no statistical differences in minimal lumen diameter before and after intervention, as well as reference diameter after stent implantation. In this study population of nondiabetic patients, pio treatment did not significantly change fasting blood glucose, fasting insulin, or glycosylated hemoglobin levels, as well as lipid parameters. In contrast, pio treatment significantly reduced neointima volume within the stented segment, with 2.3Ϯ1.1 mm 3 /mm in the pio group versus 3.1Ϯ1.6 mm 3 /mm in controls (Pϭ0.04). Total plaque volume (adventitia-lumen area) was significantly lower at follow-up in the pio group (11.2Ϯ3.2 mm 3 /mm) compared with controls (13.2Ϯ4.2 mm 3 /mm; Pϭ0.04). Moreover, the binary restenosis rate was 3.4% in the pio group versus 32.3% in controls (PϽ0.01). Conclusions-Thus, 6-month treatment with pio significantly reduced neointima volume after coronary stent implantation in nondiabetic patients. These data bolster the hypothesis that antidiabetic thiazolidinediones, in addition to their metabolic effects, exhibit direct antirestenotic effects in the vasculature.

show abstract

“…The use of alternative NIS-transported radioisotopes with a higher energy than 131 I may improve the efficacy of NIS-mediated radionuclide targeted therapy (17,18). 188 Re is a type of short physical half-life radionuclide (0.71 days), which has been applied to treat various diseases, including prostate carcinoma, hepatoma carcinoma, breast carcinoma, bladder carcinoma, refractory arthritis and coronary beta-brachytherapy (19)(20)(21)(22) …”

Section: Introductionmentioning

confidence: 99%